Kids & teens (for parents) · Georgia
Studies for children and teens in Georgia
These studies only enroll people under 18. A parent or legal guardian gives permission, and children old enough to understand are asked for their own agreement (assent).
83 recruiting studiesSource: ClinicalTrials.gov, refreshed October 26, 2026How we list studies
Studies
- RecruitingPhase 3
Long-term Safety Study of Rimegepant in Pediatric Subjects for the Acute Treatment of Migraine
Pfizer
- Location
- Decatur, GA + 54 other US sites
- Eligibility basics
- Ages 6–17
- RecruitingPhase 2
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Crinecerfont in Participants With Classic Congenital Adrenal Hyperplasia (CAH) Who Are Less Than 4 Years Old
Neurocrine Switzerland GmbH
- Location
- Atlanta, GA + 10 other US sites
- Eligibility basics
- Ages 4 mo–3
- RecruitingPhase 3
Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17)
AbbVie
- Location
- Atlanta, GA + 87 other US sites
- Eligibility basics
- Ages 6–17
- RecruitingPhase 3
A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo
Incyte Corporation
- Location
- Cumming, GA + 65 other US sites
- Eligibility basics
- Ages 2–11
- RecruitingPhase 3
A Study of Baricitinib (LY3009104) in Children From 6 Years to Less Than 18 Years of Age With Alopecia Areata
Eli Lilly and Company
- Location
- Macon, GA + 28 other US sites
- Eligibility basics
- Ages 6–17
- RecruitingPhase 3
A Study to Evaluate the Efficacy, Safety, and Drug Levels of Deucravacitinib (BMS-986165) in Adolescent Participants With Moderate to Severe Plaque Psoriasis
Bristol-Myers Squibb
- Location
- Atlanta, GA + 26 other US sites
- Eligibility basics
- Ages 12–17
- RecruitingPhase 2/Phase 3
Efficacy, Safety, and Pharmacokinetics of Vericiguat in Pediatric Participants With Heart Failure Due to Left Ventricular Systolic Dysfunction (MK-1242-036)
Merck Sharp & Dohme LLC
- Location
- Atlanta, GA + 19 other US sites
- Eligibility basics
- Ages 1 mo–17
- RecruitingPhase 3
Study to Evaluate Weight Gain as Assessed by Change in BMI Z-score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder
Alkermes, Inc.
- Location
- Decatur, GA + 14 other US sites
- Eligibility basics
- Ages 10–17
- RecruitingPhase 4
Rifaximin 200 mg Plus Oral Rehydration vs Oral Rehydration Alone in Children With Acute Diarrhea
Bausch Health Americas, Inc.
- Location
- Union City, GA + 9 other US sites
- Eligibility basics
- Ages 6–12
- RecruitingPhase 2/Phase 3
A Study to Learn About the Safety and Effects of the Study Drug PRX-102 in Children and Adolescents With Fabry Disease
Chiesi Farmaceutici S.p.A.
- Location
- Atlanta, GA + 5 other US sites
- Eligibility basics
- Ages 2–17
- RecruitingPhase 3
A Study of Dulaglutide (LY2189265) 3.0 mg and 4.5 mg in Pediatric Participants With Type 2 Diabetes Mellitus (AWARD-PEDS PLUS)
Eli Lilly and Company
- Location
- Atlanta, GA + 39 other US sites
- Eligibility basics
- Ages 10–17
- RecruitingPhase 3
A Study to Assess Change in Disease Activity and Adverse Events (AEs) With Cariprazine in the Treatment of Depressive Episodes in Pediatric Participants Participants (10 to 17 Years of Age) With Bipolar I Disorder.
AbbVie
- Location
- Decatur, GA + 30 other US sites
- Eligibility basics
- Ages 10–17
- RecruitingPhase 2
Doravirine (DOR) in Human Immunodeficiency Virus (HIV)-Infected Children Aged 4 Weeks to <12 Years and <45 kg (MK-1439-066)
Merck Sharp & Dohme LLC
- Location
- Atlanta, GA
- Eligibility basics
- Ages 1 mo–11
- RecruitingPhase 1/Phase 2
A Study of SGT-003 Gene Therapy in Duchenne Muscular Dystrophy (INSPIRE DUCHENNE)
Solid Biosciences Inc.
- Location
- Atlanta, GA + 11 other US sites
- Eligibility basics
- Ages 0 mo–17 · Men only
- RecruitingPhase 3
A Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticosteroids in Children and Infants With Moderate-to-severe Atopic Dermatitis
LEO Pharma
- Location
- Macon, GA + 13 other US sites
- Eligibility basics
- Ages 6 mo–11
- RecruitingPhase 2
A Study of Pegcetacoplan in Pediatric Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)
Apellis Pharmaceuticals, Inc.
- Location
- Atlanta, GA
- Eligibility basics
- Ages 12–17
- Recruiting
To Assess the Utility of the Point Mini in a Clinical Take-home Study
Point Designs
- Location
- Atlanta, GA
- Eligibility basics
- Ages 3–17
- RecruitingPhase 3
Evaluating the Effects of Tasimelteon vs. Placebo in Treating Pediatric Insomnia
Vanda Pharmaceuticals
- Location
- Snellville, GA + 18 other US sites
- Eligibility basics
- Ages 2–17
- RecruitingPhase 2
A Phase 2 Study of Vosoritide in Children With Idiopathic Short Stature
BioMarin Pharmaceutical
- Location
- Columbus, GA + 30 other US sites
- Eligibility basics
- Ages 3–11
- RecruitingPhase 3
A Study of Vedolizumab in Children and Teenagers With Moderate to Severe Crohn's Disease (CD)
Takeda
- Location
- Atlanta, GA + 7 other US sites
- Eligibility basics
- Ages 2–17
- RecruitingPhase 2
Evaluation of Long-Acting Lenacapavir for the Treatment of HIV-1 in Treatment-experienced Adolescents and Children
Gilead Sciences
- Location
- Atlanta, GA
- Eligibility basics
- Up to age 17
- RecruitingPhase 3
Study of a Single Dose of a 21-valent Pneumococcal Conjugate Vaccine in Children and Adolescents With Sickle Cell Disease
Sanofi
- Location
- Atlanta, GA + 4 other US sites
- Eligibility basics
- Ages 2–17
- RecruitingPhase 3
Study to Evaluate the Efficacy and Safety of Deuruxolitinib in Adolescents With Severe Alopecia Areata
Sun Pharmaceutical Industries, Inc.
- Location
- Cumming, GA + 53 other US sites
- Eligibility basics
- Ages 12–17
- RecruitingPhase 3
A Study to Evaluate the Safety, Efficacy, PK, PD and Immunogenicity of Cipaglucosidase Alfa/Miglustat in IOPD Subjects Aged 0 to <18
Amicus Therapeutics
- Location
- Atlanta, GA + 5 other US sites
- Eligibility basics
- Up to age 17